CV Exam (random stuff I need to improve) Flashcards
ranges for desirable, borderline, and high cholesterol?
- Desirable: < 200
- Borderline: 200-240
- High: > 240
NCEP ATP III ranges for optimal/desirable, near/above optimal, borderline high, high, and very high levels of LDL?
- Optimal/desirable: < 100
- Near/above optimal: 100-129
- Borderline high: 130-159
- High: 160-189
- Very high: 190+
List 5 predictive factors used to assess 10-year coronary heart disease risk based on the NCEP’s ATP III guidelines.
Age Diabetes Smoking Blood pressure categories NCEP total cholesterol categories LDL cholesterol categories
Statin effects on % reductions/increases of serum lipids:
v LDL (20-60%), v TG (10-20%), ^ HDL (5-10%)
What is SREBP?
TS factor activated by statin’s action, which increases LDL-receptor expression (binds B100)
Which statins are affected by CYP3A4 inducers/inhibitors?
LSA:
Lovastatin, sivastatin, atorvastatin
Which statins are affected by CYP2C9 inducers/inhibitors?
FR
Fluvastatin, rosuvastatin
Which statin is unaffected by CYP450 metabolism?
Pravastatin
Which statins does gemfibrozil affect, and how?
v OATP2/v Glucoronidation –> ^[all Statins]
Bile acid-binding resins (coles) effects on % reductions/increases of serum lipids:
v LDL (10-25%), small increase in TG
What enzyme is upregulated with use of bile acid-binding resins?
Cholesterol 7alpha-hydroxylase
rate-limiting step of bile acid synthesis
What is NCPL1?
Membrane protein that mediates intestinal cholesterol absorption, inhibited by ezetimibe.
Ezetimibe’s effects on % reductions/increases of serum lipids:
v LDL (~18%)
What is PCSK9?
Protease, produced by the liver, that leads to the degradation of hepatocyte LDL receptors. Inhibited by PCSK9 inhibitors evolocumab, alirocumab.
PCSK9 inhibitors’ effects on % reductions/increases of serum lipids:
v LDL (> 50%)
What is PPAR-alpha? (give detail)
Fibrates are ligands for the PPAR-alpha receptor. Leads to:
A. Decreased ApoC3/increased LPL expression –> increased FA oxidation –> decreased VLDL synthesis –> increased VLDL clearance.
B. Increased apoA1 expression –> increased HDL production.
Fibrates effects on % reductions/increases of serum lipids:
v TG (40-60%), v LDL (10-20%), ^ HDL (10-20%)
How does Niacin act?
A. Decreased lipolysis in adipocytes –> decreased FFA –> decreased VLDL.
B. Inhibits DGAT2 –> decreased VLDL synthesis.
C. ApoCIII –> increased LPL –> increased VLDL clearance.
D. Increased apoAI expression –> increased HDL production.
E. Decreased Lp(a) –> decreased thrombosis.
Niacin’s effects on % reductions/increases of serum lipids:
Effect on serum lipids: v TG (30-80%), v LDL (10-20%), ^ HDL (10-30%)
What are the names of 2 drugs used to treat homozygous FH?
give MoA of each
Lomitapide: Inhibits MTP in both erythrocytes and liver –> decreased production of chylomicrons, VLDL, and LDL
Mipomerson: Antisense oligonucleotide specific for apoB48/100 –> decreased expression of apoB48/100 –> decreased VLDL & LDLs.
What is the major side effect of lomitapide and mipomerson?
Hepatotoxicity.
Optimal triglyceride level?
Very high level?
< 150
> 500
Optimal HDL level in men? Women?
Men: >40
Women: >50
Name the 2 large vessel vasculides and their differentiating factors.
- Temporal/Giant Cell Arteritis: > 50 y/o
2. Takayasu Arteritis: Adults < 50 y/o
Read everything important about Giant Cell Arteritis.
- Granulomatous (giant cells, epitheloid cells, exudate/necrosis) vasculitis, classically involves carotid a. (headaches), but also ophthalmic (visual disturbances, jaw claudication)
- *>50 y/o, usually females
- Polyarthralgia rheumatica (morning stiffness)
- Elevated ESR, CRP
- Mutation in HLA-DR4; T cell mediated (IL-6)
- Bx reveals inflamed vessel w/giant cells, intimal fibrosis (destruction of IEL)
- MR Angio useful when larger vessel
- Tx: corticosteroids, high risk blindness w/o, anti-IL-6 AB
Read everything important about Takayasu Arteritis.
- Granulomatous (monocytes, giant cells), vasculitis, often involves aortic arch at branch pts (*collaterals form, more common than in GCA)
- Intimal hyperplasia, adventitial fibrosis
- *Adults < 50 y/o (young azn females)
- Visual sx, weak/absent pulse (“pulseless dz”), visual/neuro sx
- HTN when renal a. involved
- ESR elevated, but no specific marker
- Tx: corticosteroids, anti-IL-6 AB
Name the 2 medium vessel vasculides and their differentiating factors.
- Polyarteritis nodosa: GI, hep. B
2. Kawasaki disease: kids, heart
Read everything important about Polyarteritis Nodosa.
- Necrotizing vasculitis, multiple organs, lungs are spared
- Classically presents in young adults as HTN (renal a.), abd pain w/melena (*mesenteric a.), mononeuritis multiplex (sensory + motor; eg wrist drop), skin: livedo reticularis (rash)
- Higher incidence in hep. B pts
- Early lesion: transmural inflammation w/fibrinoid necrosis, will heal w/fibrosis (nodosa)–“string of pearls” on x-ray.
- Fatal if untreated
- Tx: corticosteroids, cyclophosphamide, long term: methotrexate
Read everything important about Kawasaki Disease.
- AKA mucocutaneous lymph node syndrome
- Typically azn children <4
- Nonspecific signs: fever, conjunctivitis, erythema to palms/soles, enlarged cervical nodes, strawberry tongue, desquamation
- *Coronary a. commonly involved: risk for thrombosis w/MI; aneurysm w/rupture
- CBC, ESR, CRP, LFT, albumin (show inflam.), echo
- Similar to PAN- less severe fibrosis
- Likely microbial agent cause; self-limited
- Tx: ASA + IV IG (but never give child w/viral syndrome ASA)
Name the 5 small vessel vasculides and their differentiating factors.
ANCA-ASSOCIATED
1. Granulomatosis w/ Polyangiitis: c-ANCA, nasopharynx
2. Eosinophilic Granulomatosis w/Polyangiitis: pANCA, asthma
3. Microscopic polyangiitis: pANCA
IMMUNE COMPLEX
1. IgA Vasculitis: antecedent infection, mostly kids
2. Cryoglobulinemic vasculitis: Hep. C
Read everything important about Granulomatosis w/Polyangiitis.
- Formerly Wegener’s Granulomatosis (“c”)
- Nectrotizing, granulomatous
- Commonly involves *nasopharynx, lungs, kidneys (“C”)
- Classic: middle-aged male w/sinusitis/nasopharyngeal ulcer, hemoptysis, bil. nodular lung infiltrates, and hematuria due to rapid progressing glomerulonephritis (can become crescentic- obliterates glumerulus)
- *c-ANCA (correlates w/dz activity)
- Also a/w saddle-nose deformity, mononeuritis multiplex, necrotizing scleritis, palpable purpura, orbital pseudotumor, etc., arthritis
- Tx: corticosteroids w/cyclophosphamide, relapses common (“c”)
Read everything important about Eosinophilic Granulomatosis w/Polyangiitis.
- Formerly Churg-Strauss Syndrome
- Nectrotizing granulomatous inflammation w/eosinophils involving multiple organs, esp. lungs + heart
- Similar to GPA, but no upper resp tract involvement (still affects triad)
- *Asthma and peripheral eosinophilia present
- *p-ANCA (correlates w/dz activity)
- Phases
1. Atopy, allergic rhinitis, asthma
2. Eosinophilia
3. Systemic vasculitis - Can also be a/w coronary arteritis (leading cause of death), cardiomyopathy, gastroenteritis
Read everything important about Microscopic Polyangiitis.
- Necrotizing vasculitis, multi-organ, esp. kidney, lung
- Fibrinoid necrosis of media; leukocytoclastic
- Similar presentation to GPA, but no nasopharyngeal involvement, no granulomas, and + *p-ANCA levels correlated w/dz activity.
- Also similar to PAN, but smaller vessels
- Tx: corticosteroids w/cyclophosphamide, relapses common. Use rituximab when severe.
Read everything important about IgA Vasculitis.
- Formerly Henoch-Schonlein Purpura
- IgA complex deposition –> complement activation
- *Mostly affects children
- *Recent antecedent infection common (usually upper respiratory tract- IgA protects mucosal sites)
- P/w palpable purpura in buttocks/legs, GI pain/bleeding, hematuria (IgA nephropathy)
- Self-limited, may recur. Steroids for severe tx.